DOCSLIB.ORG

Mouse Plekhg2 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

https://www.alphaknockout.com Mouse Plekhg2 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Plekhg2 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Plekhg2 gene (NCBI Reference Sequence: NM_138752.2 ; Ensembl: ENSMUSG00000037552 ) is located on Mouse chromosome 7. 19 exons are identified, with the ATG start codon in exon 2 and the TGA stop codon in exon 19 (Transcript: ENSMUST00000094644). Exon 5~9 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Plekhg2 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-452G7 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 5 starts from about 11.71% of the coding region. The knockout of Exon 5~9 will result in frameshift of the gene. The size of intron 4 for 5'-loxP site insertion: 1173 bp, and the size of intron 9 for 3'-loxP site insertion: 2089 bp. The size of effective cKO region: ~1753 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 5 6 7 8 9 10 19 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Plekhg2 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. It may be difficult to construct this targeting vector. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(8253bp) | A(22.15% 1828) | C(27.4% 2261) | T(22.0% 1816) | G(28.45% 2348) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. Significant high GC-content regions are found. It may be difficult to construct this targeting vector. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr7 - 28369138 28372137 3000 browser details YourSeq 102 2447 2576 3000 92.6% chr10 - 89988590 90372517 383928 browser details YourSeq 99 2447 2583 3000 84.8% chr18 - 38673185 38673317 133 browser details YourSeq 99 2450 2605 3000 89.1% chr11 + 79313544 79313697 154 browser details YourSeq 94 2405 2576 3000 92.1% chr10 + 93474671 93475184 514 browser details YourSeq 93 2447 2576 3000 92.0% chr7 - 44935345 45113497 178153 browser details YourSeq 93 2460 2579 3000 89.4% chr1 - 87810715 87810833 119 browser details YourSeq 93 2447 2576 3000 88.3% chr1 - 39524333 39524459 127 browser details YourSeq 92 2462 2576 3000 89.8% chr3 - 40911068 40911180 113 browser details YourSeq 92 2447 2576 3000 87.3% chr11 - 97649805 97649933 129 browser details YourSeq 92 2443 2583 3000 85.3% chr16 + 22267767 22267903 137 browser details YourSeq 92 2462 2585 3000 88.6% chr13 + 46766241 46766363 123 browser details YourSeq 91 2451 2583 3000 84.8% chr10 - 44938985 44939116 132 browser details YourSeq 90 2462 2576 3000 89.6% chr13 - 100563420 100563532 113 browser details YourSeq 90 2482 2602 3000 87.7% chr3 + 104841545 104841661 117 browser details YourSeq 90 2447 2576 3000 88.2% chr13 + 112521845 112521972 128 browser details YourSeq 90 2462 2583 3000 89.5% chr13 + 101160531 101160649 119 browser details YourSeq 89 2462 2576 3000 88.7% chr16 - 4917345 4917457 113 browser details YourSeq 89 2447 2576 3000 85.2% chr1 + 171172401 171172529 129 browser details YourSeq 88 2447 2576 3000 88.7% chrX - 105918094 105918221 128 Note: The 3000 bp section upstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN -------------------------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr7 - 28364385 28367384 3000 browser details YourSeq 145 948 1247 3000 92.9% chr10 + 63144135 63144677 543 browser details YourSeq 138 960 1545 3000 93.2% chr11 + 102538494 102917036 378543 browser details YourSeq 137 948 1105 3000 93.7% chr9 - 21542604 21542767 164 browser details YourSeq 137 948 1445 3000 83.3% chr10 + 76412911 76413245 335 browser details YourSeq 135 524 1079 3000 82.5% chr15 - 81484463 81484885 423 browser details YourSeq 134 948 1103 3000 94.7% chr12 + 15441039 15441201 163 browser details YourSeq 132 948 1103 3000 93.6% chr19 - 28864274 28864441 168 browser details YourSeq 131 945 1101 3000 93.0% chr18 - 67809632 67809793 162 browser details YourSeq 131 948 1095 3000 94.6% chr14 - 58814086 58814248 163 browser details YourSeq 131 948 1096 3000 92.6% chr11 - 4856562 4856709 148 browser details YourSeq 129 948 1099 3000 92.8% chr12 + 31912242 31912394 153 browser details YourSeq 128 950 1102 3000 90.6% chr12 + 70092514 70092663 150 browser details YourSeq 128 948 1102 3000 91.6% chr10 + 26750122 26750280 159 browser details YourSeq 126 941 1101 3000 89.9% chr13 - 117082458 117082618 161 browser details YourSeq 126 948 1095 3000 91.8% chr15 + 8486700 8486846 147 browser details YourSeq 126 948 1099 3000 88.6% chr10 + 78751261 78751409 149 browser details YourSeq 125 965 1099 3000 94.8% chr14 - 18260216 18260349 134 browser details YourSeq 124 965 1144 3000 92.4% chr8 - 119843040 119843252 213 browser details YourSeq 123 940 1101 3000 86.8% chr13 - 55772913 55773072 160 Note: The 3000 bp section downstream of Exon 9 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Plekhg2 pleckstrin homology domain containing, family G (with RhoGef domain) member 2 [ Mus musculus (house mouse) ] Gene ID: 101497, updated on 26-Jun-2020 Gene summary Official Symbol Plekhg2 provided by MGI Official Full Name pleckstrin homology domain containing, family G (with RhoGef domain) member 2 provided by MGI Primary source MGI:MGI:2141874 See related Ensembl:ENSMUSG00000037552 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Clg; Cslg; AI194308 Expression Broad expression in thymus adult (RPKM 36.3), spleen adult (RPKM 18.2) and 21 other tissuesS ee more Orthologs human all Genomic context Location: 7 A3; 7 16.71 cM See Plekhg2 in Genome Data Viewer Exon count: 20 Annotation release Status Assembly Chr Location 108.20200622 current GRCm38.p6 (GCF_000001635.26) 7 NC_000073.6 (28359603..28372681, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 7 NC_000073.5 (29144623..29157681, complement) Chromosome 7 - NC_000073.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 10 transcripts Gene: Plekhg2 ENSMUSG00000037552 Description pleckstrin homology domain containing, family G (with RhoGef domain) member 2 [Source:MGI Symbol;Acc:MGI:2141874] Gene Synonyms Clg Location Chromosome 7: 28,359,604-28,372,599 reverse strand. GRCm38:CM001000.2 About this gene This gene has 10 transcripts (splice variants), 99 orthologues, 20 paralogues and is a member of 1 Ensembl protein family. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Plekhg2- ENSMUST00000119990.7 4880 1340aa ENSMUSP00000112881.1 Protein coding CCDS52162 G5E8T4 TSL:1 202 GENCODE basic APPRIS ALT2 Plekhg2- ENSMUST00000094644.10 4623 1341aa ENSMUSP00000092228.4 Protein coding CCDS21040 E9QKB6 TSL:1 201 GENCODE basic APPRIS P3 Plekhg2- ENSMUST00000121085.7 4649 1365aa ENSMUSP00000113449.1 Protein coding - D3Z5N8 TSL:2 203 GENCODE basic APPRIS ALT2 Plekhg2- ENSMUST00000144700.7 3721 912aa ENSMUSP00000115651.1 Protein coding - A0A0R4J1S3 CDS 3' 206 incomplete TSL:1 Plekhg2- ENSMUST00000147362.7 729 205aa ENSMUSP00000118217.1 Protein coding - D3YY99 CDS 3' 207 incomplete TSL:3 Plekhg2- ENSMUST00000147887.1 476 63aa ENSMUSP00000122050.1 Protein coding - D3Z1B1 CDS 3' 209 incomplete TSL:3 Plekhg2- ENSMUST00000152281.1 858 56aa ENSMUSP00000117062.1 Nonsense mediated - D6RFC7 TSL:5 210 decay Plekhg2- ENSMUST00000128015.7 5511 No - Retained intron - - TSL:2 204 protein Plekhg2- ENSMUST00000129145.7 3074 No - Retained intron - - TSL:2 205 protein Plekhg2- ENSMUST00000147767.1 661 No - Retained intron - - TSL:3 208 protein Page 6 of 8 https://www.alphaknockout.com 33.00 kb Forward strand 28.35Mb 28.36Mb 28.37Mb 28.38Mb Genes Rps16-201 >protein coding Gm44710-201 >antisense (Comprehensive set... Rps16-202 >retained intron Rps16-203 >retained intron AF357399-201 >snoRNA Contigs < AC149606.6 Genes (Comprehensive set... < Plekhg2-201protein coding < Zfp36-201protein coding < Plekhg2-204retained intron < Zfp36-202protein coding < Plekhg2-202protein coding < Plekhg2-203protein coding < Plekhg2-205retained intron < Plekhg2-207protein coding < Plekhg2-206protein coding < Plekhg2-208retained intron < Plekhg2-210nonsense mediated decay < Plekhg2-209protein coding
Recommended publications
  • Open Data for Differential Network Analysis in Glioma

    Open Data for Differential Network Analysis in Glioma

    International Journal of Molecular Sciences Article Open Data for Differential Network Analysis in Glioma , Claire Jean-Quartier * y , Fleur Jeanquartier y and Andreas Holzinger Holzinger Group HCI-KDD, Institute for Medical Informatics, Statistics and Documentation, Medical University Graz, Auenbruggerplatz 2/V, 8036 Graz, Austria; [email protected] (F.J.); [email protected] (A.H.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 27 October 2019; Accepted: 3 January 2020; Published: 15 January 2020 Abstract: The complexity of cancer diseases demands bioinformatic techniques and translational research based on big data and personalized medicine. Open data enables researchers to accelerate cancer studies, save resources and foster collaboration. Several tools and programming approaches are available for analyzing data, including annotation, clustering, comparison and extrapolation, merging, enrichment, functional association and statistics. We exploit openly available data via cancer gene expression analysis, we apply refinement as well as enrichment analysis via gene ontology and conclude with graph-based visualization of involved protein interaction networks as a basis for signaling. The different databases allowed for the construction of huge networks or specified ones consisting of high-confidence interactions only. Several genes associated to glioma were isolated via a network analysis from top hub nodes as well as from an outlier analysis. The latter approach highlights a mitogen-activated protein kinase next to a member of histondeacetylases and a protein phosphatase as genes uncommonly associated with glioma. Cluster analysis from top hub nodes lists several identified glioma-associated gene products to function within protein complexes, including epidermal growth factors as well as cell cycle proteins or RAS proto-oncogenes.
  • Proteomic Identification of Potential Cancer Markers in Human Urine Using Subtractive Analysis

    Proteomic Identification of Potential Cancer Markers in Human Urine Using Subtractive Analysis

    INTERNATIONAL JOURNAL OF ONCOLOGY 48: 1921-1932, 2016 Proteomic identification of potential cancer markers in human urine using subtractive analysis HOLGER HUSI1, RICHARD J.E. SKipworth2, ANDREW Cronshaw3, KENNETH C.H. FEARON2* and JAMES A. ROSS2* 1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G12 8QQ; 2School of Clinical Sciences, 3School of Biological Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK Received November 21, 2015; Accepted December 27, 2015 DOI: 10.3892/ijo.2016.3424 Abstract. Urine is an ideal medium in which to focus diag- Introduction nostic cancer research due to the non-invasive nature and ease of sampling. Many large-scale proteomic studies have Screening of human tissues for cancer biomarkers is an impor- shown that urine is unexpectedly complex. We hypothesised tant task in cancer diagnosis and treatment, which is hindered that novel diagnostic cancer biomarkers could be discovered by the complexity of the sample systems studied. A less using a comparative proteomic analysis of pre-existing data. complex system such as urine is a preferred medium to screen We assembled a database of 100 published datasets of 5,620 for protein or peptide biomarkers due to the non-invasive urinary proteins, as well as 46 datasets of 8,620 non-redundant sampling of patients, ease of sampling and the unrestricted proteins derived from kidney and blood proteome analyses. quantities obtainable. Urine is relatively stable in terms of The data were then used to either subtract or compare mole- protein/peptide composition and fragmentation compared cules from a novel urinary proteome profiling dataset that we with other bodily fluids such as serum, where proteolytic generated.
  • Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia

    Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia

    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2021, Article ID 9863714, 16 pages https://doi.org/10.1155/2021/9863714 Research Article Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia XiaowenZhou ,1 ZhenqianYan ,1 YaxinWang ,1 QiRen ,1 XiaoqiLiu ,2 GeFang ,3 Bin Wang ,4 and Xiantao Li 1 1Laboratory of TCM Syndrome Essence and Objectification, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China 2Guangzhou Sagene Tech Co., Ltd., Guangzhou 510006, China 3College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China 4Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, China Correspondence should be addressed to Xiantao Li; [email protected] Received 22 May 2020; Revised 12 March 2021; Accepted 18 March 2021; Published 12 April 2021 Academic Editor: Jianbo Wan Copyright © 2021 Xiaowen Zhou et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Hyperlipidemia, due to the practice of unhealthy lifestyles of modern people, has been a disturbance to a large portion of population worldwide. Recently, several scholars have turned their attention to Chinese medicine (CM) to seek out a lipid-lowering approach with high efficiency and low toxicity. +is study aimed to explore the mechanism of Huatan Jiangzhuo decoction (HTJZD, a prescription of CM) in the treatment of hyperlipidemia and to determine the major regulation pathways and potential key targets involved in the treatment process.
  • A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family

    A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family

    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2018 A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family Linda Molla Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Linda Molla June 2018 © Copyright by Linda Molla 2018 A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY Linda Molla, Ph.D. The Rockefeller University 2018 APOBEC2 is a member of the AID/APOBEC cytidine deaminase family of proteins. Unlike most of AID/APOBEC, however, APOBEC2’s function remains elusive. Previous research has implicated APOBEC2 in diverse organisms and cellular processes such as muscle biology (in Mus musculus), regeneration (in Danio rerio), and development (in Xenopus laevis). APOBEC2 has also been implicated in cancer. However the enzymatic activity, substrate or physiological target(s) of APOBEC2 are unknown. For this thesis, I have combined Next Generation Sequencing (NGS) techniques with state-of-the-art molecular biology to determine the physiological targets of APOBEC2. Using a cell culture muscle differentiation system, and RNA sequencing (RNA-Seq) by polyA capture, I demonstrated that unlike the AID/APOBEC family member APOBEC1, APOBEC2 is not an RNA editor. Using the same system combined with enhanced Reduced Representation Bisulfite Sequencing (eRRBS) analyses I showed that, unlike the AID/APOBEC family member AID, APOBEC2 does not act as a 5-methyl-C deaminase.
  • Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia

    Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia

    1 Supplementary information – Postema et al., The genetics of situs inversus totalis without primary ciliary dyskinesia Table of Contents: Supplementary Methods 2 Supplementary Results 5 Supplementary References 6 Supplementary Tables and Figures Table S1. Subject characteristics 9 Table S2. Inbreeding coefficients per subject 10 Figure S1. Multidimensional scaling to capture overall genomic diversity 11 among the 30 study samples Table S3. Significantly enriched gene-sets under a recessive mutation model 12 Table S4. Broader list of candidate genes, and the sources that led to their 13 inclusion Table S5. Potential recessive and X-linked mutations in the unsolved cases 15 Table S6. Potential mutations in the unsolved cases, dominant model 22 2 1.0 Supplementary Methods 1.1 Participants Fifteen people with radiologically documented SIT, including nine without PCD and six with Kartagener syndrome, and 15 healthy controls matched for age, sex, education and handedness, were recruited from Ghent University Hospital and Middelheim Hospital Antwerp. Details about the recruitment and selection procedure have been described elsewhere (1). Briefly, among the 15 people with radiologically documented SIT, those who had symptoms reminiscent of PCD, or who were formally diagnosed with PCD according to their medical record, were categorized as having Kartagener syndrome. Those who had no reported symptoms or formal diagnosis of PCD were assigned to the non-PCD SIT group. Handedness was assessed using the Edinburgh Handedness Inventory (EHI) (2). Tables 1 and S1 give overviews of the participants and their characteristics. Note that one non-PCD SIT subject reported being forced to switch from left- to right-handedness in childhood, in which case five out of nine of the non-PCD SIT cases are naturally left-handed (Table 1, Table S1).
  • Transdifferentiation of Human Mesenchymal Stem Cells

    Transdifferentiation of Human Mesenchymal Stem Cells

    Transdifferentiation of Human Mesenchymal Stem Cells Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Tatjana Schilling aus San Miguel de Tucuman, Argentinien Würzburg, 2007 Eingereicht am: Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Martin J. Müller Gutachter: PD Dr. Norbert Schütze Gutachter: Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am: Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig angefertigt und keine anderen als die von mir angegebenen Hilfsmittel und Quellen verwendet habe. Des Weiteren erkläre ich, dass diese Arbeit weder in gleicher noch in ähnlicher Form in einem Prüfungsverfahren vorgelegen hat und ich noch keinen Promotionsversuch unternommen habe. Gerbrunn, 4. Mai 2007 Tatjana Schilling Table of contents i Table of contents 1 Summary ........................................................................................................................ 1 1.1 Summary.................................................................................................................... 1 1.2 Zusammenfassung..................................................................................................... 2 2 Introduction.................................................................................................................... 4 2.1 Osteoporosis and the fatty degeneration of the bone marrow..................................... 4 2.2 Adipose and bone
  • Supplementary Table S2. List of Genes with Expression That Is Positively Correlated (Pearson Correlation Coefficient P&gt;0.3)

    Supplementary Table S2. List of Genes with Expression That Is Positively Correlated (Pearson Correlation Coefficient P>0.3)

    Supplementary Table S2. List of genes with expression that is positively correlated (Pearson correlation coefficient p>0.3) with HOXA9 expression in the study by Sun et al (1). Most HOXA genes (indicated by bold face) show highly significant positive correlation with HOXA9 expression, except for HOXA6 and HOXA13, similar to our findings in the UCSF and MDA tumor sets. Note that HOXA11, which did not demonstrate a statistically significant positive correlation with HOXA9 expression in both the UCSF and MDA tumor sets, demonstrates a substantially lower correlation coefficient relative to the other HOXA genes that positively correlate with HOXA9 expression in the study by Sun et al. These data were obtained from the online ONCOMINE database (www.oncomine.org) (2) searching for transcripts positively correlated with HOXA9 expression. Gene Name Gene Symbol Reporter ID Correlation (p) homeobox A9 HOXA9 214651_s_at .7682 homeobox A9 HOXA9 209905_at .7682 homeobox A10 HOXA10 213150_at .6058 homeobox A7 HOXA7 235753_at .6058 homeobox A10 HOXA10 213147_at .6058 homeobox A7 HOXA7 206847_s_at .6058 homeobox A4 HOXA4 206289_at .5741 homeobox A2 HOXA2 1557051_s_at .5379 homeobox A1 HOXA1 214639_s_at .5379 homeobox A3 HOXA3 235521_at .5379 homeobox B2 HOXB2 205453_at .5379 homeobox B3 HOXB3 228904_at .5379 EST EST 1555907_at .5379 homeobox A4 HOXA4 230080_at .5379 homeobox A2 HOXA2 228642_at .5379 homeobox A2 HOXA2 1557050_at .5379 homeobox A5 HOXA5 213844_at .5379 homeobox A2 HOXA2 214457_at .5113 homeobox B7 HOXB7 204778_x_at .5042 homeobox C6 HOXC6
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards

    Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards

    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
  • Integrated Transcriptome and in Vitro Analysis Revealed Anti-Proliferative

    Integrated Transcriptome and in Vitro Analysis Revealed Anti-Proliferative

    www.nature.com/scientificreports OPEN Integrated transcriptome and in vitro analysis revealed anti-proliferative efect of citral Received: 26 November 2018 Accepted: 5 March 2019 in human stomach cancer through Published: xx xx xxxx apoptosis Sri Renukadevi Balusamy1, Sivasubramanian Ramani 1, Sathishkumar Natarajan 2, Yeon Ju Kim3 & Haribalan Perumalsamy3 Cancer is the second leading cause of death globally, particularly stomach cancer is third most common causes of cancer death worldwide. Citral possesses anti-tumor activity in various cancer cell lines, However its efect toward stomach cancer and its mechanism of action is have yet to be elucidated. The goal of the present study is to elucidate the role of citral in stomach cancer using transcriptome and in vitro approaches. We performed transcriptome analysis using RNA-seq and explored its capability to persuade apoptosis in AGS human stomach cancer cell lines in vitro. Furthermore, the enrichment and KEGG pathway results suggested that there are several genes involved to induce apoptosis pathway. Furthermore, our study also demonstrated that citral arrested colony formation and migration of cancer cells signifcantly than that of untreated cells. RNA-seq revealed a total of 125 million trimmed reads obtained from both control and citral treated groups respectively. A total number of 612 diferentially expressed genes (DEGs) were identifed which includes 216 genes up-regulated and 396 genes down- regulated genes after treatment. The enrichment analysis identifed DEGs genes from transcriptome libraries including cell death, cell cycle, apoptosis and cell growth. The present study showed the signifcant inhibition efect upon citral by regulating various genes involved in signaling pathways, inhibits metastasis, colony formation and induced apoptosis both in silico and in vitro.
  • Network Reconstruction and Significant Pathway Extraction

    Network Reconstruction and Significant Pathway Extraction

    Network Reconstruction and Significant Pathway Extraction Using Phosphoproteomic Data from Cancer Cells Marion Buffard, Aurélien Naldi, Ovidiu Radulescu, Peter Coopman, Romain Larive, Gilles Freiss To cite this version: Marion Buffard, Aurélien Naldi, Ovidiu Radulescu, Peter Coopman, Romain Larive, et al..Net- work Reconstruction and Significant Pathway Extraction Using Phosphoproteomic Data from Cancer Cells. Proteomics, Wiley-VCH Verlag, 2019, 19 (21-22), pp.1800450. 10.1002/pmic.201800450. hal- 03049205 HAL Id: hal-03049205 https://hal.archives-ouvertes.fr/hal-03049205 Submitted on 9 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Network reconstruction and significant pathway extraction using phosphoproteomic data from cancer cells BUFFARD Marion1,2, NALDI Aurélien3, RADULESCU Ovidiu2,#, COOPMAN Peter J1,#, LARIVE 5 Romain Maxime4,#,¶ and FREISS Gilles1,#,¶ # Equal contributing authors 1 IRCM, Univ Montpellier, ICM, INSERM, Montpellier, France. 10 2 DIMNP, Univ Montpellier, CNRS, Montpellier, France. 3 Computational Systems Biology Team, Institut de Biologie de l'École Normale Supérieure, Centre National de la Recherche Scientifique UMR8197, INSERM U1024, École Normale Supérieure, PSL Université, Paris, France. 4 IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France. 15 ¶ To whom correspondence should be addressed at: Gilles FREISS, IRCM, INSERM U1194, 208 rue des Apothicaires, F-34298 Montpellier cedex 5, France.
  • Biomedical Informatics

    Biomedical Informatics

    BIOMEDICAL INFORMATICS Abstract GENE LIST AUTOMATICALLY DERIVED FOR YOU (GLAD4U): DERIVING AND PRIORITIZING GENE LISTS FROM PUBMED LITERATURE JEROME JOURQUIN Thesis under the direction of Professor Bing Zhang Answering questions such as ―Which genes are related to breast cancer?‖ usually requires retrieving relevant publications through the PubMed search engine, reading these publications, and manually creating gene lists. This process is both time-consuming and prone to errors. We report GLAD4U (Gene List Automatically Derived For You), a novel, free web-based gene retrieval and prioritization tool. The quality of gene lists created by GLAD4U for three Gene Ontology terms and three disease terms was assessed using ―gold standard‖ lists curated in public databases. We also compared the performance of GLAD4U with that of another gene prioritization software, EBIMed. GLAD4U has a high overall recall. Although precision is generally low, its prioritization methods successfully rank truly relevant genes at the top of generated lists to facilitate efficient browsing. GLAD4U is simple to use, and its interface can be found at: http://bioinfo.vanderbilt.edu/glad4u. Approved ___________________________________________ Date _____________ GENE LIST AUTOMATICALLY DERIVED FOR YOU (GLAD4U): DERIVING AND PRIORITIZING GENE LISTS FROM PUBMED LITERATURE By Jérôme Jourquin Thesis Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Biomedical Informatics May, 2010 Nashville, Tennessee Approved: Professor Bing Zhang Professor Hua Xu Professor Daniel R. Masys ACKNOWLEDGEMENTS I would like to express profound gratitude to my advisor, Dr. Bing Zhang, for his invaluable support, supervision and suggestions throughout this research work.
  • PLEKHG2 CRISPR/Cas9 KO Plasmid (H): Sc-413048

    PLEKHG2 CRISPR/Cas9 KO Plasmid (H): Sc-413048

    SANTA CRUZ BIOTECHNOLOGY, INC. PLEKHG2 CRISPR/Cas9 KO Plasmid (h): sc-413048 BACKGROUND APPLICATIONS The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and PLEKHG2 CRISPR/Cas9 KO Plasmid (h) is recommended for the disruption of CRISPR-associated protein (Cas9) system is an adaptive immune response gene expression in human cells. defense mechanism used by archea and bacteria for the degradation of foreign genetic material (4,6). This mechanism can be repurposed for other 20 nt non-coding RNA sequence: guides Cas9 functions, including genomic engineering for mammalian systems, such as to a specific target location in the genomic DNA gene knockout (KO) (1,2,3,5). CRISPR/Cas9 KO Plasmid products enable the U6 promoter: drives gRNA scaffold: helps Cas9 identification and cleavage of specific genes by utilizing guide RNA (gRNA) expression of gRNA bind to target DNA sequences derived from the Genome-scale CRISPR Knock-Out (GeCKO) v2 library developed in the Zhang Laboratory at the Broad Institute (3,5). Termination signal Green Fluorescent Protein: to visually REFERENCES verify transfection CRISPR/Cas9 Knockout Plasmid CBh (chicken β-Actin 1. Cong, L., et al. 2013. Multiplex genome engineering using CRISPR/Cas hybrid) promoter: drives expression of Cas9 systems. Science 339: 819-823. 2A peptide: allows production of both Cas9 and GFP from the 2. Mali, P., et al. 2013. RNA-guided human genome engineering via Cas9. same CBh promoter Science 339: 823-826. Nuclear localization signal 3. Ran, F.A., et al. 2013. Genome engineering using the CRISPR-Cas9 system. Nuclear localization signal SpCas9 ribonuclease Nat. Protoc. 8: 2281-2308.